Table 1 Characteristics of included studies
Study | Location | Phase | Study period | Mean age (Year) | ECOG or WHO PS | Sample size (Number of case/control) | Co-treatment regimen | Celecoxib treatment program (Drugs/dosage (mg/m2)/d/frequency of cycles) |
|---|---|---|---|---|---|---|---|---|
Jin 2011 | China | II | 2005.6-2008.1 | - | 0–2 | 88(58/30) | folinic acid + fluorouracil + oxaliplatin | 200 mg twice daily no fewer than 8 weeks |
Köhne 2007 | USA | II | 2002.6-2005.11 | about 70 | 0–2 | 44(23/21) | irinotecan + FA + 5-FU | 200 mg twice daily,800 mg |
|  | USA | II | 2002.6-2005.11 | about 70 | 1–2 | 41(19/22) | irinotecan + capecitabine | 200 mg twice daily,800 mg |
Maiello 2006 | Italy | II | 2003.1-2004.12 | 64 | 0–2 | 81(41/40) | irinotecan + FA + 5-FU | 400 mg twice daily,repeated every 2weeks |
Haldar 2020 | USA | II | - | 58 | 0–2 | 34(16/18) | etodolac + propranolol | 400 mg twice daily |
Fenwick 2003 | UK | II | 2000.12-2002.2 | about 65 | 0–2 | 44(23/21) | placebo | 25 mg twice daily,rofecoxib |
Mostafa 2022 | Egypt | II | 2018.10-2020.7 | about 44 | 0–2 | 54(26/28) | irinotecan + FA + 5-FU | 200 mg twice daily last 3 months |
Niu 2010 | China | II | 2006.1-2008.12 | 56 | 0–1 | 60(30/30) | irinotecan | 200 mg twice daily |
Li 2018 | China | II | 2015.2-2016.11 | 63 | 0–2 | 122(61/61) | oxycodone hydrochloride | 200 mg twice daily last 1 months |
Meyerhardt 2021 | USA | III | 2010.6-2015.11 | 61 | 0–2 | 2524(1263/1261) | folinic acid + fluorouracil + oxaliplatin | 400 mg twice daily |
Debucquoy 2009 | USA | II | - | - | 0–2 | 80(35/45) | CRT + 5-FU | 400 mg twice daily |
Hu 2022 | China | II | 2019.5-2021.4 | 18–75 | 0–2 | 34(17/17) | toripalimab | 200 mg twice daily last 2 weeks |